GASPAR Study (LACOG 0222): Real-world data highlight the need for improvement in the care pathway of patients with gastric and pancreatic cancer in Latin America
The GASPAR study (LACOG 0222 – NCT05924789) investigates real-world data (RWD) from 122 patients with gastric cancer (Cohort A) and 79 patients with pancreatic cancer (Cohort B) in Latin America.
This observational cohort study, both retrospective and prospective, established a multicenter Latin American database in collaboration with the Argentine Group for Clinical Oncology Research (GAICO) and the Brazilian Group for Gastrointestinal Tumors (GTG).
In Cohort A, after a median follow-up of 29 months (95% CI, 18.2–50.4), the median progression-free survival (PFS) in the first-line setting was 5.6 months (95% CI, 4.2–6.3), and the median overall survival (OS) was 11.2 months (95% CI, 9.2–14.1).
In Cohort B, after a median follow-up of 21 months (95% CI, 15.6–NR), the median PFS in the first-line setting was 5.4 months (95% CI, 3.9–6.4), and the median OS was 10.2 months (95% CI, 8.6–13.1).
The GASPAR study results demonstrate that patients with gastric and pancreatic cancer in Latin America experience shorter progression-free survival compared to historical controls.
However, overall survival was comparable to previous studies.
Additionally, only 48% of gastric cancer patients and 34% of pancreatic cancer patients in the study received second-line therapy.
These findings of early disease progression and low rates of subsequent treatment lines highlight delays in diagnosis and underscore the urgent need to enhance the standard of care for these patients in Latin America.
The GASPAR study (LACOG 0222) was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), took place from January 23 to 25, 2025, in San Francisco, USA.
According to the oncologist Dr. Renata D’Alpino Peixoto, principal investigator of the study, ‘the results suggest the need for improved care for these patients in Latin America and reinforce the importance of conducting real-world epidemiological studies to identify these disparities.’
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023